File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical presentation, hematologic features and treatment outcome of childhood acute lymphoblastic leukemia: A review of 73 cases in Hong Kong

TitleClinical presentation, hematologic features and treatment outcome of childhood acute lymphoblastic leukemia: A review of 73 cases in Hong Kong
Authors
KeywordsChildhood ALL
Cytogenetics
Immunophenotype
Treatment outcome
Issue Date1997
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1997, v. 15 n. 3, p. 141-149 How to Cite?
AbstractSeventy-three consecutive cases of childhood acute lymphoblastic leukemia (ALL) diagnosed and managed in Queen Mary Hospital over a 10-year period from 1985 to 1994 were retrospectively analysed for their presenting features and treatment outcome. The 48 boys and 25 girls ranged in age from 0.4 to 14.2 years (median: 4-3 years). Bone and joint pain was a relatively common presenting feature besides fever, hepatosplenomegaly and lymphadenopathy. Immunophenotyping of blast cells showed: 51 B-cell precursor ALL, one B-ALL, 10 T-ALL and three myeloid-antigen positive ALL. Eight cases were unclassified since immunophenotyping had not been performed. Out of the 73 patients, treatment outcome was analysed in 20 cases treated with UKALL- VIII regimen and 28 cases treated with either the UKALL-XI regimen or the Hong Kong Children Cancer Study Group (HKCCSG) protocol which was modelled upon UKALL-XI. Although complete remission rates were similar between the two groups, patients treated with the former regimen that was less intensified suffered more relapses than the latter (56 per cent versus 21 per cent, P=0.04). There were, however, no significant differences both in event-free survival (38.2 ± 11.2 per cent versus 71.3 ± 9.3 per cent, P=0.12) and overall survival (70.0 ± 10.2 per cent versus 79.6 ± 8.3 per cent, P=0.41) between the two groups at 3 years by log-rank test. With the use of risk- directed therapy and improved supportive care, two-thirds of our patients are able to enjoy long-term event-free survival.
Persistent Identifierhttp://hdl.handle.net/10722/79890
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMa, SKen_HK
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorHa, SYen_HK
dc.contributor.authorChiu, DCKen_HK
dc.contributor.authorLau, YLen_HK
dc.contributor.authorChan, LCen_HK
dc.date.accessioned2010-09-06T07:59:54Z-
dc.date.available2010-09-06T07:59:54Z-
dc.date.issued1997en_HK
dc.identifier.citationHematological Oncology, 1997, v. 15 n. 3, p. 141-149en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79890-
dc.description.abstractSeventy-three consecutive cases of childhood acute lymphoblastic leukemia (ALL) diagnosed and managed in Queen Mary Hospital over a 10-year period from 1985 to 1994 were retrospectively analysed for their presenting features and treatment outcome. The 48 boys and 25 girls ranged in age from 0.4 to 14.2 years (median: 4-3 years). Bone and joint pain was a relatively common presenting feature besides fever, hepatosplenomegaly and lymphadenopathy. Immunophenotyping of blast cells showed: 51 B-cell precursor ALL, one B-ALL, 10 T-ALL and three myeloid-antigen positive ALL. Eight cases were unclassified since immunophenotyping had not been performed. Out of the 73 patients, treatment outcome was analysed in 20 cases treated with UKALL- VIII regimen and 28 cases treated with either the UKALL-XI regimen or the Hong Kong Children Cancer Study Group (HKCCSG) protocol which was modelled upon UKALL-XI. Although complete remission rates were similar between the two groups, patients treated with the former regimen that was less intensified suffered more relapses than the latter (56 per cent versus 21 per cent, P=0.04). There were, however, no significant differences both in event-free survival (38.2 ± 11.2 per cent versus 71.3 ± 9.3 per cent, P=0.12) and overall survival (70.0 ± 10.2 per cent versus 79.6 ± 8.3 per cent, P=0.41) between the two groups at 3 years by log-rank test. With the use of risk- directed therapy and improved supportive care, two-thirds of our patients are able to enjoy long-term event-free survival.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.en_HK
dc.subjectChildhood ALLen_HK
dc.subjectCytogeneticsen_HK
dc.subjectImmunophenotypeen_HK
dc.subjectTreatment outcomeen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic useen_HK
dc.subject.meshChilden_HK
dc.subject.meshChild, Preschoolen_HK
dc.subject.meshCranial Irradiationen_HK
dc.subject.meshDisease-Free Survivalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHemorrhage - etiologyen_HK
dc.subject.meshHepatomegaly - etiologyen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunophenotypingen_HK
dc.subject.meshInfanten_HK
dc.subject.meshKaryotypingen_HK
dc.subject.meshLife Tablesen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMethotrexate - administration & dosageen_HK
dc.subject.meshPain - etiologyen_HK
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma - blood - drug therapy - epidemiology - pathology - radiotherapyen_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshRemission Inductionen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshSplenomegaly - etiologyen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleClinical presentation, hematologic features and treatment outcome of childhood acute lymphoblastic leukemia: A review of 73 cases in Hong Kongen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0278-0232&volume=15&spage=141&epage=149&date=1997&atitle=Clinical+presentation,+hematologic+features+and+treatment+outcome+of+childhood+acute+lymphoblastic+leukemia:+a+review+of+73+cases+in+Hong+Kongen_HK
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_HK
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_HK
dc.identifier.emailChan, LC:chanlc@hkucc.hku.hken_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.identifier.authorityLau, YL=rp00361en_HK
dc.identifier.authorityChan, LC=rp00373en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/(SICI)1099-1069(199708)15:3<141::AID-HON608>3.0.CO;2-5en_HK
dc.identifier.pmid9600113-
dc.identifier.scopuseid_2-s2.0-0031429293en_HK
dc.identifier.hkuros31174en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031429293&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue3en_HK
dc.identifier.spage141en_HK
dc.identifier.epage149en_HK
dc.identifier.isiWOS:000073432300004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMa, SK=9042504200en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.scopusauthoridChiu, DCK=16749062300en_HK
dc.identifier.scopusauthoridLau, YL=7201403380en_HK
dc.identifier.scopusauthoridChan, LC=7403540707en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats